FRESENIUS SE &/S (OTCMKTS: FSNUY) is one of 113 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it contrast to its competitors? We will compare FRESENIUS SE &/S to related businesses based on the strength of its dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.
Earnings & Valuation
This table compares FRESENIUS SE &/S and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|FRESENIUS SE &/S||$38.28 billion||$2.05 billion||20.85|
|FRESENIUS SE &/S Competitors||$1.44 billion||$104.34 million||-168.89|
FRESENIUS SE &/S has higher revenue and earnings than its competitors. FRESENIUS SE &/S is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
FRESENIUS SE &/S has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, FRESENIUS SE &/S’s competitors have a beta of 0.81, indicating that their average stock price is 19% less volatile than the S&P 500.
Institutional & Insider Ownership
0.1% of FRESENIUS SE &/S shares are held by institutional investors. Comparatively, 49.0% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 15.8% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares FRESENIUS SE &/S and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|FRESENIUS SE &/S||5.37%||8.76%||3.52%|
|FRESENIUS SE &/S Competitors||-38.83%||-90.96%||-18.39%|
This is a summary of recent ratings and target prices for FRESENIUS SE &/S and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|FRESENIUS SE &/S||1||0||0||0||1.00|
|FRESENIUS SE &/S Competitors||640||2352||4473||211||2.55|
As a group, “Surgical & medical instruments” companies have a potential upside of 379.37%. Given FRESENIUS SE &/S’s competitors stronger consensus rating and higher probable upside, analysts clearly believe FRESENIUS SE &/S has less favorable growth aspects than its competitors.
FRESENIUS SE &/S pays an annual dividend of $0.15 per share and has a dividend yield of 0.8%. FRESENIUS SE &/S pays out 16.3% of its earnings in the form of a dividend. As a group, “Surgical & medical instruments” companies pay a dividend yield of 1.2% and pay out 32.0% of their earnings in the form of a dividend.
FRESENIUS SE &/S beats its competitors on 8 of the 15 factors compared.
FRESENIUS SE &/S Company Profile
Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis- related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products used in the collection and processing of blood components, as well as in transfusion medicine. The Fresenius Helios segment operates 111 hospitals with approximately 35,000 beds, such as 88 acute care hospitals and 23 post-acute care clinics; 4 post-acute care centers; 17 prevention centers; and 12 nursing homes. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Receive News & Ratings for FRESENIUS SE &/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FRESENIUS SE &/S and related companies with MarketBeat.com's FREE daily email newsletter.